跳至主要内容
临床试验/EUCTR2007-001326-26-DE
EUCTR2007-001326-26-DE
进行中(未招募)
不适用

A Prospective, Controlled, Randomized, Multi-Center, Phase I/II Study Evaluating the Safety and Efficacy of Adhexil™ - Using Adhexil To Prevent and/or Reduce Adhesions After Ovarian Surgery

Omrix Biopharmaceuticals Ltd.0 个研究点目标入组 25 人2007年4月25日

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Patients that undergo surgery that involves the ovaries
发起方
Omrix Biopharmaceuticals Ltd.
入组人数
25
状态
进行中(未招募)
最后更新
14年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2007年4月25日
结束日期
待定
最后更新
14年前
研究类型
Interventional clinical trial of medicinal product
性别
Female

研究者

入排标准

入选标准

  • 1\.Female patients aged 18\-45 years at screening
  • 2\.Patients undergoing elective laparoscopic surgery due to known or suspected bilateral ovarian disease
  • 3\.Patients must be willing to participate in the study, and provide written informed consent
  • 4\.Patient available and willing to undertake study visits and procedures
  • 5\.Patients of child\-bearing potential must be using a medically acceptable method of birth control throughout the study.
  • 6\.Presence of both ovaries and both intact fallopian tubes.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range

排除标准

  • 1\.Pregnant (including ectopic pregnancy) or breastfeeding patients
  • 2\.Patients whose 1LL procedure would involve enterotomy and/or cystotomy and/or urostomy, and/or postoperative hydrotubation
  • 3\.Patients whose 1LL procedure would involve surgical sterilization
  • 4\.Patients whose 1LL procedure would involve hysterectomy
  • 5\.Patients with a documented diagnosis of cancer
  • 6\.Patients with a lymphatic, hematologic or coagulation disorder
  • 7\.Known or suspected hypersensitivity to blood, blood products or any constituent of Adhexil™
  • 8\.Patients whose pre\-operative laboratory values at the baseline visit are out of normal ranges
  • 9\.Patients who are immunocompromised, possess autoimmune disorders, or who are routinely taking anticoagulants.
  • 10\.Patients who have participated in another clinical study within 30 days of enrolment.

结局指标

主要结局

未指定

相似试验

进行中(未招募)
1 期
A Prospective, Controlled, Randomized, Multi-Center, Phase I/II Study Evaluating the Safety and Efficacy of Adhexil™ - Using Adhexil To Prevent and/or Reduce Adhesions After Ovarian SurgeryPatients that undergo surgery that involves the ovariesMedDRA version: 9.1 Level: PT Classification code 10033137 Term: Ovarian cystectomy
EUCTR2007-001326-26-GBOmrix Biopharmaceuticals Ltd.25
招募中
不适用
A Prospective, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Transcatheter Aortic Valve Implantation in Female Patients who have Severe Symptomatic Aortic Stenosis Requiring Aortic Valve Replacement
NL-OMON54270Optimapharm Deutschland GmbH (formerly: SSS International Clinical Research GmbH)80
进行中(未招募)
不适用
A Prospective, Randomized, Controlled, Multi-center, (Pilot) Study of Osigraft® in Instrumented Posterolateral Fusions
EUCTR2004-000675-34-ESniversity Medical Center Utrecht150
进行中(未招募)
不适用
A prospective, controlled, randomized, multi-center, pivotal study evaluating the safety and efficacy of ADHEXIL in prevention and/or reduction of adhesions in gynecology surgeryAdhesions in gynecology surgery. Surgeries involved will be ovarian cystectomy, endometriosis, inflammation, adhesiolysisOvarian adhesion MedDRA 10067156Tubal rupture MedDRA 10067553MedDRA version: 9.1Level: LLTClassification code 10014778Term: EndometriosisMedDRA version: 9.1Level: LLTClassification code 10004433Term: Benign ovarian tumourMedDRA version: 9.1Level: LLTClassification code 10053865Term: Benign fallopian tube neoplasmMedDRA version: 9.1Level: LLTClassification code 10050697Term: Fallopian tube cystMedDRA version: 9.1Level: LLTClassification code 10061855Term: Fallopian tube neoplasmMedDRA version: 9.1Level: LLTClassification code 10048991Term: Ovarian adenomaMedDRA version: 9.1Level: LLTClassification code 10033132Term: Ovarian cystMedDRA version: 9.1Level: LLTClassification code 10033136Term: Ovarian cyst rupturedMedDRA version: 9.1Level: LLTClassification code 10064257Term: Ovarian fibromaMedDRA version: 9.1Level: LLTClassification code 10033236Term: Ovarian germ cell teratoma benignMedDRA version: 9.1Level: LLTClassification code 10061535Term: Ovarian neoplasmMedDRA version: 9.1Level: LLTClassification code 10052456Term: Parovarian cystMedDRA version: 9.1Level: LLTClassification code 10036049Term: Polycystic ovariesMedDRA version: 9.1Level: LLTClassification code 10033139Term: Ovarian disorderMedDRA version: 9.1Level: LLTClassification code 10033263Term: Ovarian haematomaMedDRA version: 9.1Level: LLTClassification code 10065741Term: Ovarian haemorrhageMedDRA version: 9.1Level: LLTClassification code 10058823Term: Ovarian massMedDRA version: 9.1Level: LLTClassification code 10033277Term: Ovarian prolapseMedDRA version: 9.1Level: LLTClassification code 10033279Term: Ovarian ruptureMedDRA version: 9.1Level: LLTClassification code 10046988Term: Varicocele ovarianMedDRA
EUCTR2009-010095-23-DEOmrix Biopharmaceuticals Ltd80
招募中
3 期
A prospective, randomized, single blind, multicentre phase III study on organ preservation with Custodiol-N solution compared with Custodiol solution in or-gan transplantation (kidney, liver and pancreas)
2024-512444-29-00Dr. Franz Koehler Chemie GmbH362